Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Mol Cancer Res. 2011 Jun 10;9(8):997–1007. doi: 10.1158/1541-7786.MCR-10-0490

Table 2.

Prevalence of EMT and stemness antigen marker expression by immunofluorescence in circulating tumor cells (intact, nucleated CK+, CD45-, DAPI + cells) from the circulation of men with metastatic castration-resistant prostate cancer (CRPC) and women with metastatic breast cancer (BC). Columns on the right indicate the number of manually scored CTCs scoring positive for each marker and the number of patients in each group who have at least one CTC that stains positive for a given marker.

Antigen n Marker-Positive CTCs (%) Patients with Marker-Positive CTCs (%)
Vimentin (CRPC) 10 108/126 (86%) 10/10 (100%)
Vimentin (BC) 10 65/97 (65%) 7/10 (70%)
N-Cadherin (CRPC) 11 205/244 (84%) 11/11 (100%)
N-Cadherin (BC) 6 78/95 (82%) 4/6 (67%)
O-Cadherin (CRPC) 6 107/120 (89%) 6/6 (100%)
CD133 (CRPC) 11 127/153 (83%) 9/11 (82%)